Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PHEN vs IBU-TAB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Management of moderate to moderately severe pain,Off-label: Acute pain, postoperative pain, chronic pain (limited use due to acetaminophen toxicity risk)
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction,Gouty arthritis (off-label),Patent ductus arteriosus closure in neonates (off-label)
1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
2-3 hours (terminal elimination half-life). Clinical context: Short half-life requires frequent dosing (every 4-6 hours) for sustained analgesic effect.
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
Hydrocodone is metabolized via CYP3A4 to hydromorphone (active) and via CYP2D6 to norhydrocodone. Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Primarily hepatic via CYP2C9; also undergoes glucuronidation. Metabolites include hydroxy- and carboxy-ibuprofen, which are inactive.
Renal (primarily as glucuronide conjugates and unchanged drug). Approximately 90-95% eliminated in urine within 24 hours; fecal excretion <5%.
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
25-35% bound to plasma proteins (mainly albumin).
Approximately 99% bound to albumin.
0.9-1.5 L/kg. Clinical meaning: Moderate Vd indicates distribution into total body water; does not extensively accumulate in tissues.
0.1-0.3 L/kg. The low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid.
Oral: 60-90% (first-pass metabolism reduces systemic availability); Rectal: 70-80%; IV/IM: 100%.
Oral: 80-100% (well absorbed). Topical: approximately 5-10% systemically absorbed (varies with formulation and application site).
GFR 30-50 m L/min: administer at 75% of usual dose every 6 hours; GFR <30 m L/min: administer at 50% of usual dose every 8 hours. Avoid in severe renal impairment.
Cr Cl 30-60 m L/min: reduce dose by 50% and avoid in Cr Cl <30 m L/min.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not recommended for children under 18 years due to risk of opioid-related adverse effects; alternative analgesics preferred.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
Initiate with lowest effective dose (e.g., acetaminophen 500 mg/hydrocodone 5 mg) every 6 hours; monitor for respiratory depression, constipation, and falls; may require dose reduction by 25-50% compared to younger adults.
Initiate at lowest effective dose (e.g., 200 mg every 8-12 hours); monitor renal function and avoid long-term use.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen (especially in children) can cause hepatotoxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants (additive respiratory depression).
NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Hepatotoxicity due to acetaminophen (dose-dependent); respiratory depression (especially in elderly, debilitated, or COPD); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; seizures; serotonin syndrome with serotonergic drugs; urinary retention; bile duct spasm; use in patients with head injury or increased intracranial pressure (risk of masking neurological signs); neonatal withdrawal syndrome.
Risk of serious GI adverse events including bleeding, ulceration, and perforation; NSAIDs should be used with caution in patients with history of peptic ulcer disease or GI bleeding. May cause renal toxicity, especially in patients with pre-existing renal impairment. Use with caution in patients with asthma, congestive heart failure, or hypertension.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment; hypersensitivity to hydrocodone, acetaminophen, or any component; use of MAO inhibitors within 14 days (hypertensive crisis).
History of hypersensitivity to ibuprofen or any other NSAID; active peptic ulcer disease or GI bleeding; severe renal impairment; history of serious cardiovascular event; perioperative pain in CABG surgery; third trimester of pregnancy.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may inhibit CYP2D6 metabolism of hydrocodone, potentially altering analgesic effect; avoid concurrent use. High-fat meals may increase absorption of hydrocodone; take consistently with or without food.
Alcohol may increase risk of GI bleeding. Food delays absorption but does not significantly affect total exposure; take with food to improve tolerability.
Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters: Prolonged use may cause neonatal withdrawal syndrome (irritability, hypertonia, respiratory depression) if used near term. Avoid use in pregnancy unless benefit outweighs risk.
First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment; avoid after 30 weeks gestation. Use not recommended during pregnancy.
HY-PHEN (hydrocodone/acetaminophen) is excreted into breast milk in low concentrations. M/P ratio for hydrocodone is approximately 2.0, for acetaminophen ~1.0. Use caution; monitor infant for sedation, respiratory depression, and poor feeding. Consider risk of neonatal withdrawal if maternal use is chronic.
Excreted in breast milk in low concentrations (M/P ratio <0.02). American Academy of Pediatrics considers compatible with breastfeeding. Monitor infant for gastrointestinal distress or rash. Use lowest effective dose for shortest duration.
No specific dose adjustments established for pregnancy. Increased plasma volume and enhanced hepatic metabolism in pregnancy may reduce drug concentrations, potentially requiring higher doses to achieve analgesic effect. However, avoid high doses due to risk of acetaminophen hepatotoxicity and fetal opioid exposure. Use lowest effective dose for shortest duration.
Increased clearance and volume of distribution in pregnancy (especially third trimester) may require dose escalation to maintain efficacy. However, due to fetal risks, avoid use; if necessary, use minimal effective dose for shortest duration.
HY-PHEN is a combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g from all sources. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; poor metabolizers may have reduced analgesia while ultra-rapid metabolizers risk toxicity. Avoid concurrent use with other CNS depressants including alcohol due to additive respiratory depression. Taper dose when discontinuing after prolonged use to prevent withdrawal.
IBU-TAB (ibuprofen) is a non-selective COX inhibitor; use lowest effective dose for shortest duration to minimize GI and renal risks. Avoid in patients with NSAID-sensitive asthma, severe renal impairment (e GFR <30 m L/min), or perioperative pain in CABG surgery. Concomitant aspirin antagonizes irreversible antiplatelet effect; separate by 2 hours if immediate-release. Monitor for fluid retention and hypertension in cardiac patients.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medicines) while using this medication to avoid liver damage.,Avoid alcohol completely while taking this drug; it increases the risk of liver damage and severe drowsiness.,Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness or drowsiness.,Store securely away from children and others; misuse can cause addiction, overdose, or death.,Do not stop taking suddenly after long-term use; your doctor will help you taper off to prevent withdrawal symptoms.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg/day without physician approval; higher doses increase risk of bleeding and kidney damage.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Discontinue and seek medical help if you experience signs of allergic reaction (rash, swelling, difficulty breathing) or black/tarry stools.,Inform your doctor about all medications you take, especially blood thinners, aspirin, other NSAIDs, and medications for blood pressure or kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PHEN vs IBU-TAB, answered by our medical review team.
HY-PHEN is a Opioid Antitussive Combination that works by HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.. IBU-TAB is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PHEN and IBU-TAB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PHEN is: 1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of IBU-TAB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PHEN and IBU-TAB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PHEN is classified as Category C. Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters:. IBU-TAB is classified as Category C. First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, ol. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.